Ocugen, Inc. (OCGN)
OCGN moved a median of -0.24% 30 minutes after news, and -0.67% by the close. How OCGN actually reacts to news — the realized, point-in-time move the market made, measured across 523 labeled events over the last three years with zero look-ahead.
OCGN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 520 |
| 30-min | -0.24% | 44% | 521 |
| 60-min | -0.35% | 45% | 521 |
| to close | -0.67% | 41% | 520 |
| Middle 50% of OCGN reactions | -2.05% to +1.56% |
|---|---|
| Median reaction (30-min) | -0.24% |
| Measured reactions | 523 |
Half of all Ocugen, Inc. news events land between -2.05% and +1.56% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How OCGN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 10 | +0.80% | 50% | +1.32% |
| Rating reiterations | 49 | +0.29% | 51% | +0.15% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how OCGN ranks against every other measured name →
That’s how OCGN usually reacts — get an email when it moves on news →Email me when OCGN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OCGN's baseline. Nothing else.
Recent OCGN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Ocugen, Inc. For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -4.14% | -3.14% | |
| Form 8-K Ocugen, Inc. For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | -4.14% | -3.14% | |
| Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Press release | GlobeNewswire | -0.65% | -5.27% | |
| Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? | Press release | PR Newswire | -0.28% | -1.31% | |
| Form 8-K Ocugen, Inc. For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | -1.89% | |
| Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate | Press release | GlobeNewswire | +0.01% | -1.89% | |
| Ocugen to Participate in Upcoming Scientific Conferences | Press release | GlobeNewswire | -0.46% | -5.50% | |
| Ocugen to Participate in Upcoming October Investor and Industry Conferences | Press release | GlobeNewswire | +2.88% | +4.81% | |
| Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa | Press release | GlobeNewswire | +0.48% | -2.86% | |
| Form 8-K Ocugen, Inc. For: Sep 21 | SEC filing · Form 8-K | SEC EDGAR | -1.42% | -5.66% | |
| Form 8-K Ocugen, Inc. For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | -6.49% | -18.70% | |
| Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Press release | GlobeNewswire | +0.08% | +0.76% | |
| Ocugen to Participate in Upcoming September Investor and Industry Conferences | Press release | GlobeNewswire | -0.72% | +0.72% | |
| Form DEFA14A Ocugen, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -2.57% | -0.73% | |
| Form 10-Q Ocugen, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.81% | |
| Form 8-K Ocugen, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.40% | -0.80% | |
| Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.40% | -0.80% | |
| Ocugen to Participate in Upcoming August Investor Conferences | Press release | GlobeNewswire | -2.03% | -4.65% | |
| Form DEF 14A Ocugen, Inc. For: Sep 21 | SEC filing · Form DEF | SEC EDGAR | -2.03% | -4.65% | |
| Form DEFA14A Ocugen, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -2.03% | -4.65% | |
| Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration | Press release | GlobeNewswire | -0.40% | -4.80% | |
| Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -0.40% | -4.80% | |
| Form PRE 14A Ocugen, Inc. For: Sep 21 | SEC filing · Form PRE | SEC EDGAR | +0.38% | -1.51% | |
| Form 8-K Ocugen, Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | -1.11% | -2.08% | |
| Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Press release | GlobeNewswire | -1.11% | -2.08% | |
| Ocugen to Participate in Upcoming July Industry Conferences | Press release | GlobeNewswire | +0.98% | -3.27% | |
| Form 8-K Ocugen, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +1.23% | -0.82% | |
| Form 8-K Ocugen, Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | +1.53% | +5.38% | |
| Ocugen to Participate in Upcoming June Investor and Industry Conferences | Press release | GlobeNewswire | -2.45% | -2.19% | |
| Form 8-K Ocugen, Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -1.04% | -3.47% | |
| Form 8-K Ocugen, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -1.04% | -3.47% | |
| Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes | Press release | GlobeNewswire | -1.04% | -3.47% | |
| Ocugen to Participate in Upcoming May Scientific and Investor Conferences | Press release | GlobeNewswire | +0.34% | -0.68% | |
| Form 10-Q Ocugen, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.69% | +0.67% | |
| Form 8-K Ocugen, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -2.69% | +0.67% | |
| Form 8-K Ocugen, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Ocugen Provides Business Update with First Quarter 2026 Financial Results | Press release | GlobeNewswire | -3.85% | -4.49% | |
| Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes | Press release | GlobeNewswire | -3.85% | -4.49% | |
| Form 8-K Ocugen, Inc. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -3.85% | -4.49% | |
| Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes | Press release | GlobeNewswire | -3.85% | -4.49% | |
| Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results | Press release | GlobeNewswire | -1.73% | +0.00% | |
| Form ARS Ocugen, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.46% | -2.92% | |
| Form DEF 14A Ocugen, Inc. For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | +1.46% | -2.92% | |
| Form DEFA14A Ocugen, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.46% | -2.92% | |
| Ocugen to Present at April 2026 Investor and Industry Conferences | Press release | GlobeNewswire | +1.46% | -2.34% | |
| Form PRER14A Ocugen, Inc. | SEC filing · Form PRER14A | SEC EDGAR | -2.39% | -5.85% | |
| Form PRE 14A Ocugen, Inc. For: Jun 11 | SEC filing · Form PRE | SEC EDGAR | -6.99% | -0.54% | |
| Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | Press release | GlobeNewswire | +0.27% | -2.72% | |
| Form 8-K Ocugen, Inc. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -1.54% | -4.10% | |
| Form 8-K Ocugen, Inc. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | -0.81% | +3.50% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OCGN section they belong to.
Where else OCGN is measured.
OCGN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ocugen, Inc.'s median reaction calculated?
Every labeled OCGN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 523 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of OCGN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OCGN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.